Koyfin Home > Directory > Health Care > Amicus Therapeutics > Long-Term Debt

Amicus Therapeutics Long-Term Debt Chart (FOLD)

Amicus Therapeutics annual/quarterly Long-Term Debt from 2009 to 2018.
  • Amicus Therapeutics Long-Term Debt for the quarter ending December 12, 2018 was $322m a 48.17% increase of 155m year over year
  • Amicus Therapeutics Long-Term Debt for the last 12 months ending December 12, 2018 was $322m a 48.17% increase of 155m year over year
  • Amicus Therapeutics Annual Long-Term Debt for 2018 was $322m a 48.98% increase of 158m from 2017
  • Amicus Therapeutics Annual Long-Term Debt for 2017 was $164m a 5.91% increase of 10m from 2016
  • Amicus Therapeutics Annual Long-Term Debt for 2016 was $154m a 73.07% increase of 113m from 2015
Other Cash Flow Metrics:
  • Amicus Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-133m a 44.44% decrease of -59m year over year
  • Amicus Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-78m a 35.32% decrease of -28m year over year
  • Amicus Therapeutics Total Revenue for the quarter ending September 09, 2018 was $21m a 28.49% increase of 6m year over year
View Chart On Koyfin

Quarterly FOLD Long-Term Debt Data

12/2018$322m
09/2018$319m
06/2018$169m
03/2018$167m
12/2017$164m
09/2017$162m
06/2017$159m
03/2017$157m
12/2016$154m
09/2016$66m

Annual FOLD Long-Term Debt Data

2018$322m
2017$164m
2016$154m
2015$42m
2014$11m
2013$14m
2012$0m
2010$1m
2009$2m